Cargando…
Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC) accounts for approximately 80% of total thyroid cancers worldwide. Although the prognosis for early‐stage PTC is favorable, the 5‐year survival rate of patients with late‐stage PTC is still very poor. Cystatin SN (cystatin 1, CST1) facilitates the progression of mul...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329778/ https://www.ncbi.nlm.nih.gov/pubmed/34102026 http://dx.doi.org/10.1002/2211-5463.13221 |